Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants

Background: The majority of coeliac disease (CD) patients are not being properly diagnosed and therefore remain untreated, leading to a greater risk of developing CD-associated complications. The major genetic risk heterodimer, HLA-DQ2 and DQ8, is already used clinically to help exclude disease. However, approximately 40% of the population carry these alleles and the majority never develop CD. Objective: We explored whether CD risk prediction can be improved by adding non-HLA-susceptible variants to common HLA testing. Design: We developed an average weighted genetic risk score with 10, 26 and 57 single nucleotide polymorphisms (SNP) in 2675 cases and 2815 controls and assessed the improvement in risk prediction provided by the non-HLA SNP. Moreover, we assessed the transferability of the genetic risk model with 26 non-HLA variants to a nested case–control population (n=1709) and a prospective cohort (n=1245) and then tested how well this model predicted CD outcome for 985 independent individuals. Results: Adding 57 non-HLA variants to HLA testing showed a statistically significant improvement compared to scores from models based on HLA only, HLA plus 10 SNP and HLA plus 26 SNP. With 57 non-HLA variants, the area under the receiver operator characteristic curve reached 0.854 compared to 0.823 for HLA only, and 11.1% of individuals were reclassified to a more accurate risk group. We show that the risk model with HLA plus 26 SNP is useful in independent populations. Conclusions: Predicting risk with 57 additional non-HLA variants improved the identification of potential CD patients. This demonstrates a possible role for combined HLA and non-HLA genetic testing in diagnostic work for CD

Biogeografía de especies de Fusarium en el litoral mediterráneo de España

El trabajo presentado estudia la presencia de Fusarium oxysporum, F.solani(sensulato), F. equiseti y F.acuminatum en puntos del litoral de Almería, Alicante, Gerona e Islas Baleares (Menorca, Ibiza, Espalmador). Se analizaron tanto arenas de las playas (zonas intermareal y supramareal) como fondos marino situados a 27,9 y 7,2 metros de profundidad en Almería y a 10 m de profundidad en las Islas Baleares. Exceptuando el litoral de Gerona, en el resto de los enclaves se presentaron varias especies de Fusarium que se aislaron de las arenas de las playas, confirmando así resultados obtenidos con anterioridad. Lo más novedoso fue encontrar especies de Fusarium a diferentes profundidades marinas. En Almería F.oxysporum y F.equisti se aislaron a 27,9 y7,2 m profundidad. F. acuminatum se aisló de la muetra recogida a 27m de profundidad. En las islas Baleares, a10m de profundidad, se aislaron F. oxysporum, F. solani (sensulato), F.equiseti y F.acuminatum. El efecto antrópico, el comportamiento como "airborne" o los arrastres de aguas por las ramblas y torrentes podría explicar la presencia de estas especies en los hábitats mencionados. La permanencia de estas especies en los hábitats mencionados, especialmente en la zona intermareal de las playas y en los fondos marinos donde soportan elevadas presiones osmóticas por la alta salinidad del agua del mar Mediterráneo, permitirá estudios específicos sobre el comportamiento de estos hongos en medios muy salinos. Otros hongos aislados de arenas de playa y fondos marinos fueron: Acremonium, Alternaria, Aspergillus, Cladosporium, Dreschlera, Gliocladium Humicola, Penicillium, Phialophora, Rhizopus, Stemphylium, Trichoderma, Trichocladium y Ulocladium. Muchos de ellos fueron aislados del fondo marino, testimoniando así que estos hábitats no son exclusivos de Fusarium

Reducción del número de parcelas de muestreo al incorporar información auxiliar LiDAR en la estimación de variables dasométricas

Reducción del número de parcelas de muestreo al incorporar información auxiliar LiDAR en la estimación de variables dasométrica

In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Current genome-editing systems generally rely on inducing DNA double-strand breaks (DSBs). This may limit their utility in clinical therapies, as unwanted mutations caused by DSBs can have deleterious effects. CRISPR/Cas9 system has recently been repurposed to enable target gene activation, allowing regulation of endogenous gene expression without creating DSBs. However, in vivo implementation of this gain-of-function system has proven difficult. Here, we report a robust system for in vivo activation of endogenous target genes through trans-epigenetic remodeling. The system relies on recruitment of Cas9 and transcriptional activation complexes to target loci by modified single guide RNAs. As proof-of-concept, we used this technology to treat mouse models of diabetes, muscular dystrophy, and acute kidney disease. Results demonstrate that CRISPR/Cas9-mediated target gene activation can be achieved in vivo, leading to measurable phenotypes and amelioration of disease symptoms. This establishes new avenues for developing targeted epigenetic therapies against human diseases. VIDEO ABSTRACT